Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

11.7K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.7K
Amyloid Fibrils03:03

Amyloid Fibrils

6.4K
6.4K
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

4.7K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
4.7K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

4.9K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.9K
What is Metabolism?00:52

What is Metabolism?

131.5K
Overview
131.5K
Peptide Bonds02:43

Peptide Bonds

82.6K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
82.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Self-Assembly of Enantiomeric Helical Dipeptides into Vesicles: Applications.

Langmuir : the ACS journal of surfaces and colloids·2026
Same author

New benzotriazole-sulfonate coupling reagents and applications.

RSC advances·2026
Same author

Intervention of hIAPP amyloid aggregation by smart post-transmuting anti-amyloidogenic peptidomimetics.

Journal of materials chemistry. B·2026
Same author

Role of Binding Site Specificity in the Disaggregation of Aβ<sub>42</sub> Fibrils via Synthetic Paratope.

ACS chemical neuroscience·2026
Same author

One-pot synthesis of ketones and symmetrical anhydrides from carboxylic acids.

RSC advances·2026
Same author

Griess's Reagent-Based Azo Compounds Ameliorate Multifaceted Toxicity and Ferroptosis in Alzheimer's Disease.

ACS chemical neuroscience·2026

Related Experiment Video

Updated: Jan 26, 2026

Assaying &#946;-amyloid Toxicity using a Transgenic C. elegans Model
13:59

Assaying β-amyloid Toxicity using a Transgenic C. elegans Model

Published on: October 9, 2010

26.6K

Engineered peptidic constructs metabolize amyloid β by self-assembly-driven reactions.

Tanmay Mondal1, Bhubaneswar Mandal

  • 1Department of Chemistry, Indian Institute of Technology Guwahati, Assam-781039, India. bmandal@iitg.ac.in.

Chemical Communications (Cambridge, England)
|April 9, 2019
PubMed
Summary

Researchers developed artificial alpha-secretases, small peptide constructs that non-catalytically cleave amyloid beta (Aβ). These novel agents initially target the alpha-secretase site, offering a new approach to Aβ degradation.

More Related Videos

Intracerebroventricular Injection of Amyloid-&#946; Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

44.3K
Synthesis and Characterization of 1,2-Dithiolane Modified Self-Assembling Peptides
09:54

Synthesis and Characterization of 1,2-Dithiolane Modified Self-Assembling Peptides

Published on: August 20, 2018

7.7K

Related Experiment Videos

Last Updated: Jan 26, 2026

Assaying &#946;-amyloid Toxicity using a Transgenic C. elegans Model
13:59

Assaying β-amyloid Toxicity using a Transgenic C. elegans Model

Published on: October 9, 2010

26.6K
Intracerebroventricular Injection of Amyloid-&#946; Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

44.3K
Synthesis and Characterization of 1,2-Dithiolane Modified Self-Assembling Peptides
09:54

Synthesis and Characterization of 1,2-Dithiolane Modified Self-Assembling Peptides

Published on: August 20, 2018

7.7K

Area of Science:

  • Biochemistry
  • Peptide Design
  • Neuroscience

Background:

  • Amyloid beta (Aβ) aggregation is a hallmark of Alzheimer's disease.
  • Proteolytic processing of Aβ involves enzymes like alpha-secretase.
  • Targeting Aβ cleavage offers therapeutic potential.

Purpose of the Study:

  • To design and characterize novel peptide-based constructs capable of cleaving amyloid beta (Aβ).
  • To investigate the non-catalytic cleavage mechanism of these constructs at the alpha-secretase site.
  • To explore the potential of these "artificial α-secretases" in Aβ degradation.

Main Methods:

  • Design of small peptide-based constructs.
  • Assaying selective recognition and cleavage of Aβ.
  • Time-resolved MALDI-TOF mass spectrometry for analysis of cleavage products.

Main Results:

  • Developed "artificial α-secretases" that selectively recognize and cleave Aβ.
  • Initial cleavage occurred near the α-secretase site in a non-catalytic manner.
  • Prolonged treatment led to cleavage at other Aβ processing sites.

Conclusions:

  • Artificial α-secretases represent a novel strategy for targeting Aβ.
  • These peptide constructs demonstrate selective and site-specific Aβ cleavage.
  • Further investigation may lead to new therapeutic avenues for Alzheimer's disease.